We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Cobalt Challenges Patents For AstraZeneca's Crestor

Law360 (November 1, 2007, 12:00 AM EDT) -- Cobalt Pharmaceuticals Inc. is seeking U.S. regulatory approval to make and sell a generic version of Astrazeneca PLC's cholesterol drug Crestor, claiming that two patents for the drug, which had U.S. sales of $696 million in the first half of 2007, are invalid, not infringed or unenforceable.

AstraZeneca received a notification letter from Canada-based generics maker Cobalt on Tuesday, saying that Cobalt submitted an Abbreviated New Drug Application to the U.S. Food and Drug Administration looking for authorization to market generic rosuvastatin calcium tablets before the...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.